Faculty of Medical and Health Sciences, University of Auckland Auckland, New Zealand.
Skeletal Radiol. 2011 Sep;40(9):1191-6. doi: 10.1007/s00256-011-1164-9. Epub 2011 Aug 17.
The bisphosphonates have revolutionized the therapy of osteoporosis, particularly the prevention of vertebral and hip fractures. The development of tools for defining absolute fracture risk facilitates their targeting to appropriate, at-risk individuals. Prescribers need to be aware of their common side effects (gastrointestinal intolerance with oral dosing and flu-like illness following intravenous use). Whether these agents carry a real risk of other problems such as osteonecrosis of the jaw and subtrochanteric fractures remains uncertain at the present time. If the association of these problems with bisphosphonates is real, it is important that the major therapeutic benefits that can accrue from bisphosphonates' appropriate targeted use are not lost as a result of the anxiety concerning these extremely rare adverse events.
双膦酸盐彻底改变了骨质疏松症的治疗方法，尤其是预防椎体和髋部骨折。定义绝对骨折风险的工具的发展促进了将其靶向用于适当的高危个体。处方医生需要了解其常见的副作用（口服给药时胃肠道不耐受和静脉使用后类似流感的疾病）。目前尚不确定这些药物是否存在其他问题（如颌骨骨坏死和转子下骨折）的真正风险。如果这些问题与双膦酸盐确实相关，那么重要的是，由于对这些极其罕见的不良事件的担忧，不会使从双膦酸盐的适当靶向使用中获得的主要治疗益处丧失。
